Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Globus Medical (GMED) a Solid Growth Stock? 3 Reasons to Think "Yes"
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
GMED or PEN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Should You Buy Globus Medical (GMED) After Golden Cross?
After reaching an important support level, Globus Medical, Inc. (GMED) could be a good stock pick from a technical perspective. GMED recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Globus Medical (GMED) is an Incredible Growth Stock: 3 Reasons Why
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical: Straightening Its Back
Globus Medical has rebounded strongly, driven by accelerating earnings and successful integration of acquisitions like NuVasive and Nevro. The company delivered on robust Q3 results, with 7% organic growth and a significant hike in full-year adjusted earnings guidance to $3.80 per share. Despite a 35% share price surge, shares trades at a reasonable 21x earnings, supported by a strong balance sheet and ongoing synergy potential.
Globus Medical, Inc. (GMED) Q3 2025 Earnings Call Transcript
Globus Medical, Inc. ( GMED ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Brian Kearns - Senior Vice President of Business Development & Investor Relations Keith Pfeil - CEO, President & Director Kyle Kline - Senior VP & CFO Conference Call Participants Richard Newitter - Truist Securities, Inc., Research Division Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Matthew Taylor - Jefferies LLC, Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Samantha Munoz - Piper Sandler & Co., Research Division David Saxon - Needham & Company, LLC, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Welcome to Globus Medical's Third Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Globus Medical (GMED) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
